About Sofregen
Sofregen is a company based in Medford (United States) founded in 2014 by Anh Hoang. Sofregen has raised $17.8 million across 2 funding rounds from investors including Anzu Partners and Polaris Partners. The company has 8 employees as of December 31, 2021. Sofregen has completed 1 acquisition, including SERI Surgical Scaffold. Sofregen offers products and services including Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform. Sofregen operates in a competitive market with competitors including Revance Therapeutics, Kerecis, Castle Creek Pharma, Organogenesis and Dermavant, among others.
- Headquarter Medford, United States
- Employees 8 as on 31 Dec, 2021
- Founders Anh Hoang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sofregen Medical Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.8 M (USD)
in 2 rounds
-
Latest Funding Round
$8.1 M (USD), Series B
Sep 03, 2019
-
Investors
Anzu Partners
& 1 more
-
Employee Count
8
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sofregen
Sofregen offers a comprehensive portfolio of products and services, including Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform.
Injectable biomaterial for vocal fold medialization and regeneration procedures.
Biomaterial scaffold for soft tissue support in surgical applications.
Platform for developing silk-based products for tissue regeneration.
People of Sofregen
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Sofregen
Sofregen has successfully raised a total of $17.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $8.1 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sofregen
Sofregen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Anzu Partners and Polaris Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in industrial and life sciences technology companies.
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Sofregen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sofregen
Sofregen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SERI Surgical Scaffold.
Investment portfolio details for Sofregen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Standalone plastic surgery hospital services are provided in Medford.
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Sofregen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sofregen
Detailed financials for Sofregen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sofregen Comparisons
Peer comparison for Sofregen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sofregen
Sofregen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Kerecis, Castle Creek Pharma, Organogenesis and Dermavant, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Fish-skin acellular dermal matrix technology is provided for wound treatments.
|
|
| Locked | Locked | Locked |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
Detailed competitors of Sofregen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sofregen
Complete news archive for Sofregen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sofregen
Sofregen was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Sofregen is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Jenna Abelli is the current CEO of Sofregen.
Sofregen is a funded company, having raised a total of $17.8M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Sofregen is 8.
Sofregen is developing the use of silk in a variety of forms to help physicians address soft tissue defects. The technology was developed at Tufts University and the University of Pittsburgh. As part of their growing portfolio of medical technologies, they have recently become the new supplier of SERI Surgical Scaffold, the only silk-based biological mesh. Unlike other products that are derived from human cadaver or animal tissue, SERI Surgical Scaffold is an ultra-pure, sterile, silk-derived bioprotein that is claimed to be delivering consistent and predictable characteristics and facilitating native tissue generation over time.
Sofregen's top competitors include Revance Therapeutics, Kerecis and Dermavant.
Sofregen offers Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform.
Sofregen has made 1 acquisition, including SERI Surgical Scaffold.
Sofregen has 2 investors. Key investors include Anzu Partners, and Polaris Partners.